Indegene Ltd., a digital tech life sciences commercialization firm, has acquired BioPharm Communications, a Pennsylvania-based healthcare marketing agency, in a bid to expand its AI-driven AdTech capabilities for global pharmaceutical clients.
The deal, executed through Indegene’s US subsidiary ILSL Inc., aims to strengthen the company’s omnichannel and media offerings by integrating BioPharm’s precision marketing expertise with Indegene’s data and analytics platforms. Financial terms of the transaction were not disclosed.
BioPharm is a part of Omnicom Health Group prior to the acquisition, brings proprietary access to over three million healthcare decision-makers.
Founded in 2005, BioPharm serves 17 of the world’s top 25 biopharma companies and specializes in data-driven campaign execution, media strategy, and targeted engagement. The acquisition is expected to enhance Indegene’s ability to deliver scalable, measurable outcomes for pharma clients navigating increasingly complex commercialization landscapes.
“BioPharm has built an impressive growth flywheel,” said Manish Gupta, Chairman and CEO of Indegene. “This acquisition reinforces our position as the preferred tech-native commercialization partner for life sciences.”
Steve Carickhoff, President of BioPharm, said the merger comes at a pivotal time for the industry. “Indegene’s contextualized approach to AI will open up new possibilities, helping us deliver deeper value to clients,” he said.
The move comes as pharmaceutical companies face mounting pressure to modernize their marketing strategies amid evolving regulatory demands and shifting physician engagement models. Traditional healthcare agencies are struggling to keep pace, prompting a shift toward specialized, AI-first solution providers.
Indegene said the combined entity will leverage vast data assets to drive higher media ROI and enable more effective agentic operations. The company was represented by Seyfarth Shaw LLP in the transaction.
Indegene’s investors include marquee names such as Capital Research its largest public shareholder, Fidelity International, Premji Invest, Enam Family Office, SBI MF and Sundaram MF.
The deal was announced after the market hours. Shares of Indegene rose 0.65% to close at Rs.565.15.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
